Global Bronchodilators Market 2017-2021

Overview of the global bronchodilators market

Research analysis on the global bronchodilators market identified the growing focus towards the development of mAb will be one of the major factors boosting the market’s growth during the forecast period. With the rising use of mAbs for the asthma treatment, the vendors in the market are increasingly focusing on the development of mAb.

Vendors such as AtraZeneca and Sanofi already have drugs in the later stage of development. mAbs show positive results and are expected to help in the market’s growth due to their high uptake owing to the better efficacy of the other small molecules. Technavio’s market research analysts predict that this market will grow at a CAGR of almost 5% by 2021.

Get A Free Sample

Bronchodilators market trends

The new forms of drug administration will lead to the growth of the market, owing to the higher intake of drugs. The vendors in the market are investing heavily in the development of different kinds of asthma inhalers and nebulizers that provide easy access to the patients. Ultrasonic nebulizers that comprise better technology compared to the jet nebulizers are currently available in the market. In addition, the shift of market towards electronic systems technology such as electronic health record will also boost the market’s growth during the forecast period.

Bronchodilators market growth: Competitive landscape and key vendors

The bronchodilators market is highly competitive and is characterized by the presence of key players including AstraZeneca and GlaxoSmithKline. Aggressive pricing and new indications are the major factors the competition among the players is based on. To increase their revenue shares, the vendors focus on both the distribution channels such as direct sales and distributors.

The leading vendors in the bronchodilators market

• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• F. Hoffmann-La Roche

Bronchodilators market segmentation by product type

• Anticholinergic bronchodilators
• Adrenergic bronchodilators
• Bronchodilator combinations
• Methylxanthines

The anticholinergics bronchodilators segment accounts for the major shares of this market. In addition to protecting the airways from spasms, anticholinergics also reduce the amount of mucus produced by the airways. The use of anticholinergics results in reduced hospitalizations and mortality due to COPD. Owing to the wide availability of drugs, this segment will exhibit significant growth during the next four years as well.

Bronchodilators market forecast based on geographical segmentation

• Americas
• APAC
• EMEA

The Americas generated the highest revenue for the market due to the increasing number of cases for asthma and COPD. COPD is considered as the third deadly disease in the region. The rising awareness about the disease coupled with the new approval of drugs will drive the growth of bronchodilators market in the Americas.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global bronchodilators market?
• What are the key market trends impacting the growth of the global bronchodilators market?
• What are the challenges to market growth?
• Who are the key vendors in the global bronchodilators market?
• What are the market opportunities and threats faced by the vendors in the global bronchodilators market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global bronchodilators market?

Technavio also offers customization on reports based on specific client requirement.